Xixian Urology Summit Forum was successfully held at the First People's Hospital of Xianyang City

On June 17, the second phase of the Xixian Urology Summit Forum and the new choice of academic seminars of prostate cancer endocrine therapy were successfully held at the First People's Hospital of Xianyang City to provide everyone with urinary tumor sharing platform. The meeting invited Yuan Jianlin, President of the Men's Association of the Shaanxi Medical Association, and the well -known urology experts in the province. More than 50 colleagues in the city attended the meeting. Yu Liping, deputy dean of the First People's Hospital of Xianyang City, attended the meeting.

Professor Yuan Jianlin, president of the Shaanxi Medical Association Men's Association, delivered a speech to the conference to express warm congratulations to the meeting of this meeting. The achievements achieved by urology are very appreciated and relieved.

In his speech, the deputy dean of the city's first house, Yu Liping, highly affirmed the development of urological disciplines. I hope that experts, professors, and colleagues can use this meeting to adopt the strengths of the public, enhance exchanges, open up their horizons, and gain friendship. Through sharing, exchanges, and learning to effectively promote the academic development of urological sciences in Xixian, the development of urological development of grass -roots medical units in Xi'an, Xianyang and even the provinces, and make positive contributions to promoting the scientific and technological progress of the urology industry and the development of local health.

At the meeting, Professor Wu Guojun, Dean Wu Guojun, Dean of the Xi'an People's Hospital Urinary Kidney Hospital shared the "Latest Progress in the Field of the Prostate Cancer from 2022 ASCO-GU Update", showing the latest scientific information of prostate cancer endocrine therapy; the second affiliated to Xi'an Jiaotong University Professor Li Hecheng, deputy director of the hospital urology department, shared the "Viewing Patients from Apatamine PSA for a long time", analyzed the comparison of the preferred scheme of the drug selection of prostate cancer endocrine therapy, and unveiled the mysterious veil of prostate cancer endocrine therapy ; Li Nan, director of the Department of Urology, Xianyang Central Hospital, shared the "New Upgrade Structure, Preferably Apahamine", which reproduced the new choice of drugs for endocrine therapy of prostate cancer; The MHSPC case sharing, through examples to relive the "new weapon" of endocrine therapy of prostate cancer with the present experts.

During the meeting, young doctors conducted fierce discussions on endocrine therapy of prostate cancer. Experts and professors shared clinical and surgery experience without reservation, hoping to benefit more patients.

Academic Association ended successfully in a warm atmosphere. Professor Yuan Jianlin summarized the conference. The content of the academic conference was depth, comprehensive, and novel. Essence Through the discussion of this academic conference, it laid a good foundation for better the treatment of prostate cancer in the future. (Reporter Han Yongguo)

- END -